Trials that use: Multiplicity adjustment
New to this method? Read the tutorial →
10,417 results
- Safety and Performance of HiRes Ultra/Ultra 3D Cl Mid-Scala Electrodes in Adults With Severe-to-profound Hearing Loss: Complete Statistical AnalysisIndependent statistical analysis of Safety and Performance of HiRes Ultra/Ultra 3D Cl Mid-Scala Electrodes in Adults With Severe-to-profound Hearing Loss: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Performance of Miami InnFocus Drainage Implant (MIDI Arrow) Glaucoma Drainage Implant: Complete Statistical AnalysisIndependent statistical analysis of Safety and Performance of Miami InnFocus Drainage Implant (MIDI Arrow) Glaucoma Drainage Implant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Performance Study of the Harpoon Mitral Valve Repair System: Complete Statistical AnalysisIndependent statistical analysis of Safety and Performance Study of the Harpoon Mitral Valve Repair System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents: Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia: Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc): Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency: Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016): Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016): primary endpoint results, effect estimate with…
- Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV): Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00845650).
- Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS): Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS): Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (Anagrelide Hydrochloride) Compared to Other Treatments: Complete Statistical AnalysisIndependent statistical analysis of Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (Anagrelide Hydrochloride) Compared to Other Treatments: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn: Complete Statistical AnalysisIndependent statistical analysis of Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals’ IPV Vaccine (PoliorixTM) in Toddlers: Complete Statistical AnalysisIndependent statistical analysis of Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in Toddlers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients: Complete Statistical AnalysisIndependent statistical analysis of Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Tolerability of Artificial Tears in Dry Eye Subjects: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability of Artificial Tears in Dry Eye Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00932477).
- Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055): Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Tolerability of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Tolerability of Seroguard Use: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability of Seroguard Use: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03640559).
- Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Tolerability Study of N6022 in Healthy Subjects: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability Study of N6022 in Healthy Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01147406).
- Safety And Tolerability Study Of RN564 In Women With Osteopenia And Healthy Men.: Complete Statistical AnalysisIndependent statistical analysis of Safety And Tolerability Study Of RN564 In Women With Osteopenia And Healthy Men.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy: Complete Statistical AnalysisIndependent statistical analysis of Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety and Tolerability Study of SHP626 in Overweight and Obese Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability Study of SHP626 in Overweight and Obese Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00593606).
- Safety Evaluation of Aline HA, an Implanted Cross-Linked HA Device: Complete Statistical AnalysisIndependent statistical analysis of Safety Evaluation of Aline HA, an Implanted Cross-Linked HA Device: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01708213).
- Safety Evaluation of an Experimental Treatment, Intradermal Human Fcγ1-Fel d1 Fusion Protein (GFD), for Cat Allergy: Complete Statistical AnalysisIndependent statistical analysis of Safety Evaluation of an Experimental Treatment, Intradermal Human Fcγ1-Fel d1 Fusion Protein (GFD), for Cat Allergy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety Extension Study Of Tanezumab When Administered By Subcutaneous Injection To Patients With Osteoarthritis: Complete Statistical AnalysisIndependent statistical analysis of Safety Extension Study Of Tanezumab When Administered By Subcutaneous Injection To Patients With Osteoarthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD: Complete Statistical AnalysisIndependent statistical analysis of Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD: primary endpoint results, effect estimate with…
- Safety of 4CMenB Exposure During Pregnancy: Complete Statistical AnalysisIndependent statistical analysis of Safety of 4CMenB Exposure During Pregnancy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02640677).
- Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals’ Boostrix™ Vaccine in Healthy Vietnamese Children: Complete Statistical AnalysisIndependent statistical analysis of Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6: Complete Statistical AnalysisIndependent statistical analysis of Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04084171).
- Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR: Complete Statistical AnalysisIndependent statistical analysis of Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to
- Safety of Buprenorphine Transdermal Patch (BTDS) in Osteoarthritis Pain: a 52-Week Extension Phase: Complete Statistical AnalysisIndependent statistical analysis of Safety of Buprenorphine Transdermal Patch (BTDS) in Osteoarthritis Pain: a 52-Week Extension Phase: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety of Buprenorphine Transdermal System (BTDS) in Subjects With Acute Postoperative Pain After Total Knee Replacement: Complete Statistical AnalysisIndependent statistical analysis of Safety of Buprenorphine Transdermal System (BTDS) in Subjects With Acute Postoperative Pain After Total Knee Replacement: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.: Complete Statistical AnalysisIndependent statistical analysis of Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.: primary endpoint results, effect estimate with confidence interval, sample-size…
- Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma: Complete Statistical AnalysisIndependent statistical analysis of Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval,…
- Safety of Intravenous Apramycin in Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety of Intravenous Apramycin in Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05590728).
- Safety of Intravenous Neridronic Acid in CRPS: Complete Statistical AnalysisIndependent statistical analysis of Safety of Intravenous Neridronic Acid in CRPS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02972359).
- Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea: Complete Statistical AnalysisIndependent statistical analysis of Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea: primary endpoint results,…